M. Fuji et al. / Open Journal of Psychiatry 1 (2011) 132-136 135
and delusions. Although our patient had a past history of
Pneumocystis pneumonia and cytomegalovirus retinitis,
he had no clear history of central nervous system infec-
tion other than the retinitis. Since both a process of im-
provement of the consciousness disorder and resolution
of the mental symptoms were observed in regard to the
patient’s hallucinations and delusions, the course of treat-
ment appeared to be different from that of schizophrenia.
In the future it seems that it will be necessary to bear in
mind HIV encephalopathy cases such as our own, in
which the patient exhibited mental symptoms, including
hallucinations and delusions, as a result of a longterm
central nervous system disturbance, and examine the
patients even when their CD4 cell count is adequate. At
age 28, our patient’s CD4 cell count was below 10/μl in
September, and he developed cytomegalovirus retinitis
as a complication. It was estimated that he had probably
contracted the HIV infection more than 20 years previ-
ously. After infection in the periphery, HIV rapidly mi-
grates centrally, and it causes behavior disorders, motor
disorders, and cognitive dysfunction. Our patient’s mother
had schizophrenia, but it is unclear whether that contrib-
uted to his vulnerability to hallucinations and delusions.
The powerful antiviral therapy call HAART was in-
troduced in Japan about 10 years ago, and the number of
patients who die of HIV infection declined, but at that
time there was a very harsh situation in which life and
death were governed by whether HAART had been in-
troduced in the AIDS unit. Our patient had been admit-
ted to the internal medicine department of hospital A for
Pneumocystis pneumonia 3 years before, but at that time
HAART had not been established, and presumably the
patient became depressed and planned to commit suicide
as a result of anxiety of about dying because of seeing
patients around him die day after day and thinking that
one day the same would probably happen to him. The
patient developed cytomegalovirus retinitis as a compli-
cation at precisely that time, and he was one of the first
patients to receive the benefits of HAART after it be-
came available in Japan. Some of the drugs used in
HAART easily pass through the blood-brain barrier, and
others do not. Zidovudine has the highest transfer rate of
the drugs used to treat our patient, i.e., zidovudine,
lamivudine, and nelfinavir, and it has been reported to be
effective against HIV encephalopathy. 7) The fact that
only a 200 mg dose of zidovudine, i.e., one third the
usual dose, could be used in our patient because of im-
paired hematopoiesis may have played a role in the de-
velopment of the HIV encephalopathy.
Before HAART was established, HIV encephalopathy
was observed in 10% - 40% of AIDS patients, but at
present the proportion has declined to 10.5%. On the
other hand, the life span of HIV patients has increased as
a result of the advent of HAART, and the number of pa-
tients like our own who develop HIV encephalopathy
despite receiving HAART has risen, 4) Symptoms of
HIV encephalopathy, such as cognitive dysfunction, mem-
ory disorders, etc., greatly reduce the QOL (quality of
life) of patients with HIV infection. When, as in our own
patient, a long time has passed after being infected, ef-
forts at early detection and prevention of progression of
HIV encephalopathy by means of the HIV Dementia
Scale and even more precise psychological tests, 8) and
quantitative determinations of viral load in cerebrospinal
fluid and other substances that serve as markers, 9) seem
necessary, even in cases that have been well controlled
by HAART.
4. CONCLUSIONS
HIV testing of schizophrenia patients is rare in Japan. As
in our own patient, if there is no advance information in
relation to HIV, there is a strong possibility of HIV en-
cephalopathy not being detected or taking too long to
diagnose. Even though it is rare, it is necessary to recon-
sider including HIV encephalopathy in the differential
diagnosis of schizophrenia patients in routine clinical
practice.
REFERENCES
[1] Hashimoto, R., Mukai, E., Yokomaku,-Y., Mamiya, N.
and Hamaguchi, M. (2008) Clinical features and courses
of 5 cases with HIV encephalopathy. Clinical Neurology,
48, 173-178.
[2] World Health Organization. (2008) World health statis-
tics, 13-14.
[3] Nakashima, Y., Inoue, M. and Isse, K. (2002) Psychiatric
problems of AIDS and related disorder. Japanese Journal
of Clinical Psychiatry, 31, 925.
[4] Kopnisky, K.L. and Bao, J. (2007) HIV Preclinical thera-
peutics research: Central nervous system approaches.
Journal of Neuroimmune Pharmacology, 2, 1.
[5] Bhaskaran, K., Mussini, C., Antinori, A., Walker, A.S.,
Dorrucci, M., Sabin, C., Phillips, A. and Porter, K. (2008)
CASCADE collaboration. Change in the incidence and
predictors of human immunodeficiency virus-associated
dementia in the era of highly active antiretrovairal ther-
apy. Annals of Neurology, 63, 213-221.
doi:10.1002/ana.21225
[6] Uehira, T. and Shirasaka, T. (2001) HIV-associated cog-
nitive-motor complex/AIDS dementia complex. Clinic
All-Round, 50, 2738.
[7] Simpson, D.M. (1999) Human immunodeficiency vi-
rus-associated dementia: Review of pathogenesis, pro-
phylaxis, and treatment studies of zidovudine therapy.
Clinical Infectious Disease, 29, 19-34.
doi:10.1086/520150
[8] Bottiggi, K.A., Chang, J.J., Schmitt, F.A., Avison, M.J.,
Mootoor, Y., Nath, A. and Berger J.R. (2007) The HIV
dementia scale: Predictive power in mild dementia and
HAART. Journal of the Neurological Sciences, 260, 11-
15. doi:10.1016/j.jns.2006.03.023
C
opyright © 2011 SciRes. OJPsych